Financial Data and Key Metrics Changes - The company reported strong quarterly free cash flow of $92 million, reflecting its long-term cash generation potential [9] - Adjusted EBITDA margins for the TSS business increased to 32%, up from 31% in the prior year, despite additional costs of approximately $22 million in R&D investments [10] - For the full year 2026, the company anticipates overall net sales growth to be between 3% and 5%, with Adjusted EBITDA expected to range from $800 million to $900 million [26] Business Line Data and Key Metrics Changes - The TSS business achieved record sales for Opteon refrigerants, with a 37% increase compared to the prior year quarter, driven by higher pricing and moderate volume increases [9][10] - The TT business is expected to see sequential net sales decrease in the low- to mid-single digits percentage range in the first quarter, with mineral sales anticipated to drop 60% sequentially [18][19] - The APM business is projected to experience a high teens percentage decrease in net sales sequentially due to sustained market weakness and the impact of a facility outage [21] Market Data and Key Metrics Changes - The company noted a strengthening order book in the semiconductor sector, indicating preliminary signs of recovery in the APM business [13] - The TT segment is experiencing stable demand with no major demand triggers expected, while pricing power remains strong [38][72] - The company anticipates that average global pricing for TiO2 pigment will be generally in line with the prior year quarter [19] Company Strategy and Development Direction - The company is focused on executing its Pathway to Thrive strategy, which emphasizes operational excellence, cost management, and cash flow generation [29][35] - The recent sale of the Kuan Yin facility is expected to generate approximately $300 million in net proceeds, which will be used to reduce debt and improve the net leverage ratio [6][27] - The company is committed to enhancing its market position through innovation and strategic portfolio management, including the closure of underperforming sites [32][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to generate cash flow and improve earnings throughout 2026, despite facing challenges in certain end markets [24][35] - The company expects to see continued growth in the TSS business driven by regulatory adoption and market demand for Opteon refrigerants [16][17] - Management highlighted the importance of maintaining operational stability and reliability in light of recent disruptions at key manufacturing facilities [13][14] Other Important Information - The company has made significant progress in reducing corporate-level expenses compared to the same quarter last year, reflecting ongoing efforts in expense management [15] - The company plans to invest approximately $5 million per quarter in liquid cooling and next-generation refrigerant growth opportunities [31] Q&A Session Summary Question: Can you share more detail on the assumptions for TiO2 volume growth in your 2026 guidance? - Management indicated that demand is stable with no major triggers, and they are focused on pricing power [38] Question: Do you have visibility on resolving legacy liabilities during 2026? - Management noted significant progress in addressing legacy liabilities, particularly in New Jersey, and expects updates on other facilities throughout the year [39] Question: Can you provide insights on the APM segment's performance across different end markets? - Management highlighted weaknesses in auto and industrial sectors but noted strong demand in the Performance Solutions portfolio, particularly related to AI and data centers [44] Question: What factors could lead to achieving the high end of your guidance range for the full year? - Management mentioned market evolution, cost improvements, and continued execution on pricing as key factors [78] Question: How do you see the growth algorithm for the TSS business evolving? - Management expects significant growth from the HFO transition and a recovery in the residential segment as new units are put on the market [81]

The Chemours Company (NYSE:CC) Q4 2025 Earnings call February 20, 2026 08:00 AM ET Company ParticipantsBrandon Ontjes - VP, Head of Strategy and Investor RelationsDenise Dignam - President and CEOHassan Ahmed - Co-Founder and Head of ResearchJohn Roberts - Managing DirectorJosh Spector - Executive Director of Chemicals Equity ResearchPeter Osterland - VP of Equity ResearchShane W. Hostetter - SVP and CFOVincent Andrews - Managing DirectorConference Call ParticipantsArun Viswanathan - Senior Equity AnalystDu ...

The Chemours Company (NYSE:CC) Q4 2025 Earnings call February 20, 2026 08:00 AM ET Speaker8Good morning. My name is Carmen, and I'll be your conference operator today. I would like to welcome everyone to the Chemours Company Fourth Quarter 2025 Results Conference Call. Currently, all participants are in a listen-only mode. A question-and-answer session will follow the conclusion of the prepared remarks. I would like to remind everyone that this conference call is being recorded. I would now like to hand the ...

Chemours reports quarterly earnings per share of 5 cents, 2 cents lighter than Wall Street expectations. ...

Economic Indicators - US stock index futures experienced a slight decline ahead of key economic data releases and a potential Supreme Court ruling on Trump's tariff policies [2][12] - The upcoming US Q4 GDP report is expected to show a growth of 2.5%, down from a previous 4.4% in Q3 [3][12] - The PCE price index is anticipated to rise by 2.8% year-over-year, with the core PCE expected to increase by 3% [3][12] - There is a division among Federal Reserve policymakers regarding concerns over the labor market and inflation, with inflation rates still above the Fed's 2% target [3][12] Market Reactions - The market is currently stagnant, awaiting catalysts such as the Supreme Court ruling and Nvidia's upcoming earnings report, which may induce volatility [4][13] - The S&P 500 index has remained flat year-to-date, while the Nasdaq index has seen a decline, indicating sector rotation and broadening market participation [4][13] Corporate Earnings and Performance - Grail's stock plummeted by 47% after its drug trial failed to meet primary endpoints [16] - Opendoor Technologies' stock surged by 19% following a Q4 revenue of $736 million, exceeding market expectations of $549 million [16] - Akamai Technologies' stock fell approximately 10% due to Q1 earnings guidance that did not meet expectations [16] - Comfort Systems reported a Q4 EPS of $9.37, surpassing expectations of $6.75, with revenue of $2.65 billion, significantly above the forecast of $2.34 billion [18] Tariff Impact on Businesses - JPMorgan's report indicates that US mid-sized businesses have been severely impacted by tariffs, with monthly tariff expenditures tripling since early 2025 [15] - Tariff expenditures account for about 10% of international spending for all mid-sized US businesses, rising to approximately 15% for those paying tariffs [15] - Research shows that US businesses and consumers bear 96% of the tariff costs, with 43% of these costs passed on to consumer prices [15][7] Commodity Prices - Goldman Sachs forecasts that gold prices will gradually rise to $5,400 per ounce by the end of 2026, driven by central bank demand and increased private investment [5][14]

THE CHEMOURS COMPANY Q4 & FULL YEAR 2025 EARNINGS PRESENTATION February 20, 2026 Safe Harbor Statement and Other Matters This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or ...

Core Viewpoint - Chemours reported a revenue of $1.33 billion for the quarter ended December 2025, reflecting a 2.2% decline year-over-year, with an EPS of $0.05 compared to $0.11 in the same quarter last year, indicating a significant EPS surprise of +2400% against a consensus estimate of $0 [1] Revenue Performance - Revenues from the Other Segment were $12 million, slightly below the average estimate of $12.65 million, marking a year-over-year decline of -7.7% [4] - Titanium Technologies generated revenues of $561 million, exceeding the average estimate of $548.65 million, but still showing an -11.2% year-over-year decrease [4] - Advanced Performance Materials reported revenues of $312 million, surpassing the estimated $302.82 million, yet reflecting a -3.7% change compared to the previous year [4] - Thermal & Specialized Solutions achieved revenues of $444 million, slightly below the estimated $447.37 million, but showing a positive year-over-year change of +13.9% [4] Adjusted EBITDA Analysis - Adjusted EBITDA for Titanium Technologies was $23 million, exceeding the average estimate of $17.47 million [4] - The Other Segment's Adjusted EBITDA was $1 million, compared to the average estimate of $0.87 million [4] - Advanced Performance Materials reported an Adjusted EBITDA of $12 million, significantly lower than the estimated $34.36 million [4] - Thermal & Specialized Solutions had an Adjusted EBITDA of $128 million, which was below the average estimate of $135.12 million [4] Stock Performance - Chemours shares have returned +30.6% over the past month, contrasting with a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

分组1 - Chemours reported quarterly earnings of $0.05 per share, exceeding the Zacks Consensus Estimate of breakeven, but down from $0.11 per share a year ago, representing an earnings surprise of +2,400.00% [1] - The company posted revenues of $1.33 billion for the quarter ended December 2025, aligning with the Zacks Consensus Estimate, but down from $1.36 billion year-over-year [2] - Chemours shares have increased approximately 79.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.20 on revenues of $1.43 billion, and for the current fiscal year, it is $1.70 on revenues of $6.04 billion [7] - The Zacks Industry Rank for Chemical - Diversified is currently in the bottom 23% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8] - The estimate revisions trend for Chemours was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]

Financial Performance - Q4 2025 Net Sales were $1.3 billion, down 2% year-over-year, primarily due to a 4% decrease in volume, partially offset by a 1% price increase and a 1% currency tailwind [7]. - Q4 2025 Net Loss attributable to Chemours was $47 million, or $0.31 per diluted share, compared to a Net Loss of $11 million, or $0.08 per diluted share in Q4 2024 [8]. - Adjusted EBITDA for Q4 2025 was $128 million, down 24% from $168 million in the prior-year quarter, driven by higher costs impacting net loss [8]. - Full year 2025 Net Sales were $5.8 billion, flat compared to the prior year, with TSS reporting record annual sales driven by higher volume and price [9]. - Full year 2025 Net Loss attributable to Chemours was $386 million, or $2.57 per diluted share, compared to Net Income of $69 million, or $0.46 per diluted share in the prior year [10]. - Adjusted EBITDA for the full year 2025 was $742 million, down from $768 million in the prior year, primarily due to lower pricing and cost absorption issues [10]. Segment Performance - TSS segment Q4 2025 Net Sales were $444 million, a 14% increase year-over-year, driven by a 10% price increase and a 3% volume increase [12]. - TiO2 segment Q4 2025 Net Sales were $561 million, an 11% decrease year-over-year, primarily due to a 6% decrease in price globally [17]. - APM segment Q4 2025 Net Sales were $312 million, a 4% decrease year-over-year, primarily driven by an 8% decrease in volume [21]. - APM segment Q4 2025 Adjusted EBITDA decreased 74% to $12 million, primarily due to a non-cash inventory charge and a less favorable product mix [23]. - APM segment full year 2025 Net Sales were $1.3 billion, a 5% decrease compared to full year 2024, primarily due to weaker global demand [25]. - Adjusted EBITDA for APM decreased 32% from the prior year to $108 million, driven by lower cost absorption and operational disruptions [25]. - Other Non-Reportable Segment had Net Sales of $50 million and Adjusted EBITDA of $8 million for the full year 2025 [26]. Cash Flow and Debt - Free Cash Flows for Q4 2025 were $92 million, reflecting a Free Cash Flow Conversion of 72%, compared to $29 million or 17% in Q4 2024 [30]. - As of December 31, 2025, consolidated gross debt was $4.2 billion, with a net leverage ratio of approximately 4.7x on a trailing twelve-month Adjusted EBITDA basis [28]. - Cash provided by operating activities was $264 million for the year ended December 31, 2025, a significant improvement from cash used of $633 million in 2024 [51]. - Cash used for investing activities was $206 million for the year ended December 31, 2025, compared to $353 million in 2024 [51]. - The company issued $748 million in new debt during the year ended December 31, 2025, compared to $606 million in 2024 [51]. Future Outlook - The Company anticipates consolidated Net Sales to increase by 3 to 5% in Q1 2026, with Adjusted EBITDA expected to range between $120 million and $150 million [31]. - The Company expects 2026 Net Sales growth in the range of 3 to 5% and Adjusted EBITDA of $800 million to $900 million [37]. - Capital expenditures for 2026 are anticipated to range from $275 million to $325 million, with Free Cash Flow Conversion above 25% [37]. - Estimated Free Cash Flows for the year ending December 31, 2026, are projected to be between $200 million and $270 million [67]. - Estimated Adjusted EBITDA for the year ending December 31, 2026, is expected to range from $800 million to $900 million [68]. - Net income attributable to Chemours for the year ending December 31, 2026, is estimated to be between $165 million and $225 million [68]. - Adjusted Net Income for the year ending December 31, 2026, is projected to be between $130 million and $180 million [68]. Legal and Environmental Charges - The company incurred restructuring and asset-related charges of $58 million for the year ended December 31, 2025, primarily related to the exit of the SPS Capstone™ business [59]. - Litigation-related charges for the year ended December 31, 2025, amounted to $320 million, significantly impacting the financial results due to various legal settlements [59]. - Environmental charges for the year ended December 31, 2025, included $93 million related to remediation expenses, reflecting ongoing liabilities [59]. Shareholder Information - Basic loss per share for the year ended December 31, 2025, was $(2.57), while adjusted diluted earnings per share were $0.95, down from $1.20 in 2024 [62]. - The weighted-average number of common shares outstanding for the year ended December 31, 2025, was approximately 150.8 million [62].

Core Insights - The Chemours Company reported a net loss of $386 million for the full year 2025, compared to a net income of $69 million in 2024, primarily due to litigation-related charges and lower pricing in the Titanium Technologies segment [1][3][5] - Adjusted EBITDA for 2025 was $742 million, a decrease from $768 million in the previous year, reflecting challenges in pricing and production levels [1][3][5] - The company anticipates consolidated net sales growth of 3% to 5% for 2026, driven by increased demand in Thermal & Specialized Solutions and Advanced Performance Materials [1][3][5] Fourth Quarter 2025 Results - Net sales for Q4 2025 were $1.3 billion, down 2% year-over-year, with a notable 37% growth in Opteon™ Refrigerants [1][2] - Adjusted EBITDA for Q4 2025 was $128 million, a decline of 24% from $168 million in Q4 2024 [1][2] - The net loss attributable to Chemours in Q4 2025 was $47 million, compared to a loss of $11 million in the same quarter of the previous year [1][2] Segment Performance Thermal & Specialized Solutions (TSS) - TSS reported Q4 2025 net sales of $444 million, a 14% increase year-over-year, driven by a 10% price increase and a 3% volume increase [2][3] - Full year 2025 net sales for TSS reached a record $2.1 billion, up 13% from 2024, with Opteon™ Refrigerants growing by 56% [2][3] Titanium Technologies (TT) - TT's Q4 2025 net sales were $561 million, an 11% decrease compared to Q4 2024, primarily due to a 6% decrease in pricing [2][3] - Full year 2025 net sales for TT were $2.4 billion, down 6% from the previous year, attributed to weaker demand and pricing [2][3] Advanced Performance Materials (APM) - APM's Q4 2025 net sales were $312 million, a 4% decrease year-over-year, driven by an 8% decline in volume [2][3] - Full year 2025 net sales for APM were $1.3 billion, down 5% from 2024, reflecting weaker global demand [2][3] Financial Outlook - The company expects free cash flow conversion to exceed 25% in 2026, with adjusted EBITDA projected between $800 million and $900 million [1][3] - Capital expenditures for 2026 are anticipated to range from $275 million to $325 million, with a focus on improving cash flow and debt profile [1][3]